Age-related macular degeneration

Prescribing Notes:

• Vascular endothelial growth factor inhibitors (ranibizumab, aflibercept, faricimab and brolocizumab) are included on the formulary for the treatment of neovascular (wet) age-related macular degeneration (AMD). Vascular endothelial growth factor inhibitors are only to be administered by specialists experienced in the management of diabetic macular oedema.
• A brolucizumab MHRA drug safety update highlighted a risk of intraocular inflammation and retinal vascular occlusion which increases with short dosing intervals. Maintenance doses of brolucizumab (after the first 3 doses) should not be given at intervals of less than 8 weeks apart.